20.17
3.77%
-0.79
HUTCHMED (China) Limited ADR (HCM) 最新ニュース
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board ... - Yahoo Finance UK
Yahoo Finance UK
HUTCHMED (LON:HCM) Stock Crosses Above 200-Day Moving Average of $271.21 - Defense World
Defense World
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
GlobeNewswire Inc.
TCOM: 3 China Stocks to Watch in May - StockNews.com
StockNews.com
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
GlobeNewswire Inc.
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
GlobeNewswire Inc.
HUTCHMED (LON:HCM) Shares Pass Above 200-Day Moving Average of $268.65 - Defense World
Defense World
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
Zacks Investment Research
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? - Zacks Investment Research
Zacks Investment Research
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
GlobeNewswire Inc.
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
GlobeNewswire Inc.
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
GlobeNewswire Inc.
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
GlobeNewswire Inc.
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
GlobeNewswire Inc.
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Benzinga
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
GlobeNewswire Inc.
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Zacks Investment Research
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
GlobeNewswire Inc.
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
GlobeNewswire Inc.
HUTCHMED to Announce 2023 Final Results
GlobeNewswire Inc.
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
GlobeNewswire Inc.
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
GlobeNewswire Inc.
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
GlobeNewswire Inc.
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
GlobeNewswire Inc.
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
GlobeNewswire Inc.
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga
When companies leave AIM for Nasdaq: is the grass greener? - Interactive Investor
Interactive Investor
Nio, Xpeng and 86 others added to SEC's list of firms facing possible delisting - CnEVPost
CnEVPost
What Happens to Your ETFs if Chinese ADRs Delist? - Morningstar HK
Morningstar HK
Are Delistings of Chinese Stocks on Their Way? - Morningstar
Morningstar
HCM HUTCHMED (China) Limited - Quantisnow
Quantisnow
Trinity Delta Equity Research & Stock Reports - Research Tree
Research Tree
HUTCHMED (HCM) Stock Price, News & Analysis - MarketBeat
MarketBeat
大文字化:
|
ボリューム (24 時間):